Isocitrate dehydrogenase mutation and microenvironment in gliomas: Do immunotherapy approaches matter?
Purpose of review - Gliomas with mutations in the gene for isocitrate dehydrogenase (IDH) display a unique immune microenvironment that is distinct from IDH-wildtype gliomas. This unique immune microenvironment is shaped by 2-hydroxyglutarate (2-HG), an oncometabolite produced by mutant I...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
December 2025
|
| In: |
Current opinion in neurology
Year: 2025, Jahrgang: 38, Heft: 6, Pages: 706-710 |
| ISSN: | 1473-6551 |
| DOI: | 10.1097/WCO.0000000000001426 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1097/WCO.0000000000001426 Verlag, lizenzpflichtig, Volltext: https://journals.lww.com/co-neurology/abstract/2025/12000/isocitrate_dehydrogenase_mutation_and.13.aspx 
|
| Verfasserangaben: | Michael Platten |
MARC
| LEADER | 00000naa a22000002c 4500 | ||
|---|---|---|---|
| 001 | 194301504X | ||
| 003 | DE-627 | ||
| 005 | 20251201112859.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 251201s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/WCO.0000000000001426 |2 doi | |
| 035 | |a (DE-627)194301504X | ||
| 035 | |a (DE-599)KXP194301504X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Platten, Michael |d 1971- |e VerfasserIn |0 (DE-588)121627780 |0 (DE-627)081431848 |0 (DE-576)261969811 |4 aut | |
| 245 | 1 | 0 | |a Isocitrate dehydrogenase mutation and microenvironment in gliomas |b Do immunotherapy approaches matter? |c Michael Platten |
| 264 | 1 | |c December 2025 | |
| 300 | |a 5 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 01.12.2025 | ||
| 520 | |a Purpose of review - Gliomas with mutations in the gene for isocitrate dehydrogenase (IDH) display a unique immune microenvironment that is distinct from IDH-wildtype gliomas. This unique immune microenvironment is shaped by 2-hydroxyglutarate (2-HG), an oncometabolite produced by mutant IDH. These features provide an opportunity to develop and test targeted immunotherapies for IDH-mutant gliomas. - Recent findings - IDH-mutant gliomas are characterized by an immunosuppressive tumor immune microenvironment (TIME) that suppresses the infiltration and activation of tumor-specific T cells. This is owed both to direct effects of the oncometabolite 2-hydroxyglutarate on glioma-infiltrating T cells and myeloid cells and indirect effects on the chemotactic profile of tumor cells. These immunosuppressive effects are reversed by IDH inhibitors recently approved for the treatments of IDH-mutant gliomas. At the same time, clinical trials have demonstrated encouraging results for targeted immunotherapies using vaccines targeting the most frequent mutation IDH1R132H. - Summary - The reversal of the immunosuppressive effects by IDH inhibitors has opened exciting avenues for combinatorial immunotherapies such as vaccines and immune checkpoint inhibitors. | ||
| 773 | 0 | 8 | |i Enthalten in |t Current opinion in neurology |d London : Lippincott Williams & Wilkins, 1993 |g 38(2025), 6 vom: Dez., Seite 706-710 |h Online-Ressource |w (DE-627)324455704 |w (DE-600)2026967-5 |w (DE-576)093981074 |x 1473-6551 |7 nnas |a Isocitrate dehydrogenase mutation and microenvironment in gliomas Do immunotherapy approaches matter? |
| 773 | 1 | 8 | |g volume:38 |g year:2025 |g number:6 |g month:12 |g pages:706-710 |g extent:5 |a Isocitrate dehydrogenase mutation and microenvironment in gliomas Do immunotherapy approaches matter? |
| 856 | 4 | 0 | |u https://doi.org/10.1097/WCO.0000000000001426 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://journals.lww.com/co-neurology/abstract/2025/12000/isocitrate_dehydrogenase_mutation_and.13.aspx |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20251201 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 121627780 |a Platten, Michael |m 121627780:Platten, Michael |d 60000 |d 65100 |e 60000PP121627780 |e 65100PP121627780 |k 0/60000/ |k 1/60000/65100/ |p 1 |x j |y j | ||
| 999 | |a KXP-PPN194301504X |e 4818197696 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"role":"aut","given":"Michael","family":"Platten","display":"Platten, Michael"}],"relHost":[{"language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 23.11.20"],"id":{"zdb":["2026967-5"],"issn":["1473-6551"],"eki":["324455704"]},"title":[{"title":"Current opinion in neurology","title_sort":"Current opinion in neurology"}],"part":{"pages":"706-710","issue":"6","text":"38(2025), 6 vom: Dez., Seite 706-710","extent":"5","year":"2025","volume":"38"},"origin":[{"dateIssuedDisp":"1993-","dateIssuedKey":"1993","publisherPlace":"London ; [Erscheinungsort nicht ermittelbar]","publisher":"Lippincott Williams & Wilkins ; Ovid"}],"pubHistory":["6.1993,5 -"],"disp":"Isocitrate dehydrogenase mutation and microenvironment in gliomas Do immunotherapy approaches matter?Current opinion in neurology","physDesc":[{"extent":"Online-Ressource"}],"recId":"324455704"}],"origin":[{"dateIssuedKey":"2025","dateIssuedDisp":"December 2025"}],"title":[{"subtitle":"Do immunotherapy approaches matter?","title":"Isocitrate dehydrogenase mutation and microenvironment in gliomas","title_sort":"Isocitrate dehydrogenase mutation and microenvironment in gliomas"}],"note":["Gesehen am 01.12.2025"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"language":["eng"],"recId":"194301504X","physDesc":[{"extent":"5 S."}],"name":{"displayForm":["Michael Platten"]},"id":{"doi":["10.1097/WCO.0000000000001426"],"eki":["194301504X"]}} | ||
| SRT | |a PLATTENMICISOCITRATE2025 | ||